Moleculin Biotech Inc reports results for the quarter ended in March - Earnings Summary

Moleculin Biotech

11/05/2023 14:32

* Moleculin Biotech Inc  MBRX.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended in March. The
mean expectation of two analysts for the quarter was for a loss
of 25 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Moleculin Biotech Inc's reported EPS for the quarter was a
loss
of 28 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Moleculin Biotech Inc shares had fallen by 18.7% this
quarter and lost 26.4% so far this year.
    * The company reported a quarterly loss of $7.92 million.
    * Wall Street's median 12-month price target for Moleculin
Biotech
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.25          -0.28          Missed
 Dec. 31 2022      -0.30          -0.23          Beat
 Sep. 30 2022      -0.27          -0.30          Missed
 Jun. 30 2022      -0.25          -0.24          Beat